Galvani E, Mundra P, Valpione S, et al. Low tumour heterogeneity but not mutational burden correlates with response to anti-PD-1 treatment in a mouse model of melanoma. SMR 2017, abstract SMR4-04.
Tucatinib verlengt mediane overleving met 5,5 maand in finale analyse HER2CLIMB-studie
mrt 2022 | Borstkanker